# A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

> **NCT07229625** · PHASE3 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 604 (estimated)

## Conditions studied

- Advanced Biliary Tract Cancer

## Interventions

- **DRUG:** SHR-8068 Injection
- **DRUG:** Adebrelimab Injection
- **DRUG:** Gemcitabine Hydrochloride for Injection
- **DRUG:** Cisplatin Injection
- **DRUG:** Durvalumab Injection

## Key facts

- **NCT ID:** NCT07229625
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-21
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 604 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07229625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07229625, "A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07229625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*